Benralizumab

Covers benralizumab as add‑on maintenance therapy for severe eosinophilic asthma in patients ≥12 years old who have failed/been inadequate on at least 3 months of controller therapy (e.g., ICS+LABA or other specified controllers), have uncontrolled disease with frequent/severe exacerbations, and meet eosinophil thresholds (≥150 cells/μL at screening or ≥300 cells/μL in the prior year). Coverage is subject to the member’s HCSC Ohio benefit plan and policy criteria, excludes age <12, use with other antiasthmatic monoclonal antibodies, acute bronchospasm/status asthmaticus, and non–self‑administered formulations are allowed only when patients/caregivers cannot safely recognize/treat anaphylaxis or perform injections; off‑label use requires compendia support or two peer‑reviewed articles.

"Coverage, exclusions, and any dollar caps or limitations are determined by the member's benefit plan, summary plan description, or contract."